A Pharmacokinetic Study of CKD-501 in Patients With Impaired Hepatic Function Compared With Normal Hepatic Function

Trial Profile

A Pharmacokinetic Study of CKD-501 in Patients With Impaired Hepatic Function Compared With Normal Hepatic Function

Completed
Phase of Trial: Phase I

Latest Information Update: 22 Aug 2016

At a glance

  • Drugs Lobeglitazone (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacokinetics
  • Sponsors Chong Kun Dang
  • Most Recent Events

    • 08 Jul 2016 Status changed from recruiting to completed.
    • 22 May 2014 Planned End Date changed from 1 Dec 2015 to 1 May 2016 as reported by ClinicalTrials.gov.
    • 22 May 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top